Compare · CPUH vs IBER
CPUH vs IBER
Side-by-side comparison of Compute Health Acquisition Corp. (CPUH) and Ibere Pharmaceuticals (IBER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CPUH and IBER operate in Blank Checks (Finance), so they compete in similar markets.
- CPUH is the larger of the two at $1.05B, about 6.3x IBER ($167.2M).
Compute Health Acquisition Corp.
Compute Health Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Wilmington, Delaware.
Ibere Pharmaceuticals
Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
Latest CPUH
- SEC Form 15-12G filed by Compute Health Acquisition Corp.
- SEC Form 4: Compute Health Sponsor Llc was granted 2,088,327 shares and returned 2,088,327 shares to the company (Amendment)
- SEC Form 4: Harsh Michael was granted 21,120 shares and returned 31,120 shares to the company, closing all direct ownership in the company
- SEC Form 4: Watanabe Gwendolyn A was granted 21,120 shares and returned 21,120 shares to the company
- SEC Form 25-NSE filed by Compute Health Acquisition Corp.
- Allurion Debuts as a Publicly Traded Company on the NYSE
- SEC Form DEFA14A filed by Compute Health Acquisition Corp.
- Compute Health Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Compute Health Acquisition Corp. Stockholders Approve Business Combination with Allurion
- SEC Form 425 filed by Compute Health Acquisition Corp.
Latest IBER
- SEC Form 15-12G filed by Ibere Pharmaceuticals
- SEC Form 25-NSE filed by Ibere Pharmaceuticals
- Ibere Pharmaceuticals filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ibere Pharmaceuticals Will Redeem All Outstanding Ordinary Shares Included In Units Issued In IPO Effective As Of Close Of Business On March 2; Per-Share Redemption Price For Public Shares Will Be ~$10.17; Expects That NYSE Will File Form 25 To Delist Co
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form 10-Q filed by Ibere Pharmaceuticals